Edwards Lifesciences (EW) Cash & Current Investments (2009 - 2026)

Edwards Lifesciences' Cash & Current Investments history runs 18 years deep, the most recent figure standing at $3.7 billion for Q1 2026.

• In Q1 2026, Cash & Current Investments fell 5.82% year-over-year to $3.7 billion; the TTM figure through Mar 2026 stood at $3.7 billion (down 5.82% YoY), while the FY2025 annual figure was $4.2 billion, up 6.3% from the prior year.
• Cash & Current Investments was $3.7 billion for Q1 2026 at Edwards Lifesciences, down from $4.2 billion in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $4.4 billion in Q3 2024 to a low of $1.2 billion in Q4 2022.
• Historically, Cash & Current Investments has averaged $2.6 billion across 5 years, with a median of $1.9 billion in 2023.
• The sharpest annual moves came in 2022 and 2024: Cash & Current Investments declined 17.66% in 2022, then surged 143.5% in 2024.
• A 5-year view of Cash & Current Investments shows it stood at $1.2 billion in 2022, then surged by 35.19% to $1.6 billion in 2023, then soared by 143.5% to $4.0 billion in 2024, then rose by 6.3% to $4.2 billion in 2025, then slipped by 13.13% to $3.7 billion in 2026.
• The last three Cash & Current Investments figures came in at $3.7 billion (Q1 2026), $4.2 billion (Q4 2025), and $3.8 billion (Q3 2025), per Business Quant data.